Navigation Links
MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
Date:6/28/2008

MOUNTAIN VIEW, Calif., June 28 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (IV) DHE. The study results were among six posters relating to the MAP0004 program that the Company presented at the American Headache Society 50th Annual Scientific Meeting in Boston, MA.

In this receptor pharmacology study, MAP0004 stimulated receptors that relieve migraine at levels comparable to IV DHE, but did not activate receptors associated with side effects frequently seen with IV DHE. In addition, MAP0004 did not affect receptors that have a role in regulating pulmonary function.

"The selective binding of MAP0004 at receptors associated with migraine rather than those associated with side effects offers a mechanistic hypothesis for the favorable safety and efficacy profile of MAP0004 compared to IV DHE that we have observed in our initial clinical studies," said Thomas A. Armer, Ph.D., Chief Scientific Officer of MAP Pharmaceuticals. "The absence of negative effects of MAP0004 on pulmonary function in asthmatic subjects observed in a Phase 2 study is also important because migraine and asthma are frequently co-morbid conditions."

MAP0004 is designed to be self-administered by patients at home via MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In Phase 2 studies with migraneurs and with asthmatics, treatment with MAP0004 was well-tolerated, with no serious adverse events reported. Drug-induced nausea was very low and migraine-associated nausea also decreased with treatment.

The Company presented a poster summariz
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
6. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
7. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
8. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Insulet Corporation (NASDAQ: PODD ), the ... ® Insulin Management System, today announced preliminary revenue ... The Company also announced that it will postpone the ... conference call from Thursday, July 30, as originally scheduled. ... , Preliminary second quarter revenue ...
(Date:7/29/2015)... 2015  UBM Canon brings MEDevice San Diego Conference ... Marina on September 1-2, 2015, with a multi-track conference ... the Business Development track will be a panel on ... Investors, featuring Renee Ryan , Vice President of ... Ahrens , Partner, Canaan Partners; and Jordan Kramer ...
(Date:7/29/2015)... 2015  According to data released today by the ... monthly Medicare Part D premium is expected to remain ... originally projected, the Pharmaceutical Care Management Association (PCMA) said. ... be a bright spot in American health care. By ... and using cutting edge, cost-saving tools like pharmacy networks ...
Breaking Medicine Technology:Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex Farnoosh, ... surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned ... many patients from around the world. , “Like treatment of any other disease or ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute (TCI) ... National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of 69 ...
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial and ... from the AC units and ventilation systems on hospital roofs. Bird droppings can carry ... virus. When these droppings dry, the fine powder can be carried into hospitals via ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
(Date:7/30/2015)... ... 30, 2015 , ... After a three year trial designed to study the ... as the “bionic eye,” researchers have determined the trial to be a success, and ... or already affected by complete vision loss as a result of Retinitis pigmentosa. The ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... (April 19, 2010) -- The University of South Florida (USF) ... health records, with the support of a $5.9 million ... last week. "The University of South Florida is the ... and now is one of just a handful of universities ...
... ... the MTA,s zero-tolerance policy on the usage of cell phones despite this driver,s violent disagreement ... New ... being told by a supervisor that he should not talk on the phone while driving. ...
... at the University of Alabama at Birmingham (UAB) Department ... that will help predict which patients are more likely ... The findings also shed light on the genetics that ... with Caucasians, the researchers said. In data presented ...
... activity in the brain can affect language development in ... more frequently on children with severe language impairment to ... reveals a thesis from the Sahlgrenska Academy at the ... children of varying ages, divided into groups. The first ...
... smoke-free settings, but doctors have concerns, , MONDAY, April ... Reynolds launched Camel Orbs, dissolvable nicotine pellets flavored with ... smokers who find themselves in smoke-free surroundings. , But ... Pediatrics warn that the product, which can ...
... at the University of Alabama at Birmingham (UAB) Department ... that will help predict which patients are more likely ... The findings also shed light on the genetics that ... with Caucasians, the researchers said. In data presented ...
Cached Medicine News:Health News:PaperFree Florida to help move physicians towards electronic health records 2Health News:PaperFree Florida to help move physicians towards electronic health records 3Health News:David Perecman Comments On Bus Driver Assaulting Supervisor In New York 2Health News:UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis 2Health News:Language dysfunction in children may be due to epileptic brain activity 2Health News:Kids Could Overdose From Nicotine-Laced 'Candy' 2Health News:UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis 2
... of any biological activity but appears to ... of insulin. Although insulin and C-Peptide are ... fasting levels of C-Peptide are 5-10 fold ... the longer half-life of C-Peptide. The glucagon ...
... The Array Multifocal IOL was designed ... with independence from glasses in most situations. ... IOL is similar to that of a ... usually much better and about 19 in ...
Inquire...
... IgG Enzymelinked Immunosorbent Assays(ELISA) is intended for ... antibody to Measles Rubeola) virus in human ... for the determination of immune status. Paired ... demonstrate seroconversion or a significant rise in ...
Medicine Products: